In brief
Health authorities are investigating 13 cases of infant botulism across 10 states, linked to two lots of ByHeart's Whole Nutrition Infant Formula. The FDA announced a recall as all affected infants were hospitalized after consuming the formula. Parents are urged to clean surfaces and seek medical attention if their infants show symptoms.
Health officials are currently investigating 13 reported cases of infant botulism that are linked to a baby formula recalled by ByHeart Inc. The Food and Drug Administration (FDA) announced on Saturday that the company is recalling two specific lots of its Whole Nutrition Infant Formula due to safety concerns.
Following the consumption of the recalled formula from lots: 206VABP/251261P2 and 206VABP/251131P2, all 13 affected infants were initially hospitalized. These cases have been reported in states including Arizona, California, Illinois, Minnesota, New Jersey, Oregon, Pennsylvania, Rhode Island, Texas, and Washington.
Fortunately, no fatalities have been reported. The FDA is currently investigating the source of contamination and whether other products may be affected by the same issue.
The affected formula, which accounted for about 1% of national formula sales according to the Centers for Disease Control and Prevention (CDC), is available both online and through major retailers.
The CDC has advised parents who purchased the recalled formula to take note of the lot number before disposing of it or returning it to the retailer. It recommends that parents use a dishwasher or hot, soapy water to thoroughly clean any items or surfaces that may have come into contact with the formula.
If an infant has consumed the recalled formula and exhibits signs such as poor feeding, loss of head control, difficulty swallowing, or decreased facial expression, parents should seek medical attention immediately.
Infant botulism is caused by a bacterium that produces toxins in the intestines, and symptoms can take weeks to manifest, emphasizing the need for vigilance among parents, warns the CDC.
As of now, a representative from ByHeart has not responded to inquiries for further comment.
